title: Efavirenz enhances HIV-1 gag processing at the plasma membrane through Gag-Pol dimerization.
abstract: Efavirenz (EFV), a nonnucleoside reverse transcriptase (RT) inhibitor, also inhibits HIV-1 particle release through enhanced Gag/Gag-Pol processing by protease (PR). To better understand the mechanisms of the EFV-mediated enhancement of Gag processing, we examined the intracellular localization of Gag/Gag-Pol processing products and their precursors. Confocal microscopy revealed that in the presence of EFV, the N-terminal p17 matrix (p17MA) fragment was uniformly distributed at the plasma membrane (PM) but the central p24 capsid (p24CA) and the Pol-encoded RT antigens were diffusely distributed in the cytoplasm, and all of the above were observed in puncta at the PM in the absence of EFV. EFV did not impair PM targeting of Gag/Gag-Pol precursors. Membrane flotation analysis confirmed these findings. Such uniform distribution of p17MA at the PM was not seen by overexpression of Gag-Pol and was suppressed when EFV-resistant HIV-1 was used. Forster's fluorescence resonance energy transfer assay revealed that Gag-Pol precursor dimerization occurred mainly at the PM and that EFV induced a significant increase of the Gag-Pol dimerization at the PM. Gag-Pol dimerization was not enhanced when HIV-1 contained the EFV resistance mutation in RT. Bacterial two-hybrid assay showed that EFV enhanced the dimerization of PR-RT fragments and restored the dimerization impaired by the dimerization-defective mutation in the RT tryptophan repeat motif but not that impaired by the mutation at the PR dimer interface. Collectively, our data indicate that EFV enhances Gag-Pol precursor dimerization, likely after PM targeting but before complete particle assembly, resulting in uniform distribution of p17MA to and dissociation of p24CA and RT from the PM.
authors.affiliation: Kitasato University, Minato-ku, Tokyo, Japan.
authors.forename: Sho
authors.initials: S
authors.lastname: Sudo
authors.forename: Hiyori
authors.initials: H
authors.lastname: Haraguchi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hirai
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Gatanaga
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Sakuragi
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Momose
authors.forename: Yuko
authors.initials: Y
authors.lastname: Morikawa
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology; D048588:Benzoxazines / Q000494:pharmacology*; D002462:Cell Membrane / Q000737:chemistry / Q000378:metabolism*; D003521:Cyclopropanes; D003593:Cytoplasm / Q000737:chemistry; D031541:Fluorescence Resonance Energy Transfer; D015497:HIV-1 / Q000187:drug effects*; D006367:HeLa Cells; D006801:Humans; D018613:Microscopy, Confocal; D055503:Protein Multimerization; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D020798:Two-Hybrid System Techniques; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*; D054302:pol Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D054301:gag Gene Products, Human Immunodeficiency Virus; D054302:pol Gene Products, Human Immunodeficiency Virus; C098320:efavirenz